HIGHLIGHTS
- who: Sasan Ghaffari from the The Affiliated Nanjing Drum Tower, Hospital of Nanjing University, Medical School/China have published the Article: CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy, in the Journal: (JOURNAL)
- what: The authors aim to review and categorize the recent breakthroughs of genetically modified TCR/CAR T-cells through technology and address the pearls and pitfalls of each method. The authors investigate the latest ongoing clinical trials that are applying CRISPR-associated TCR/CAR T-cells for the treatment of cancers. In this review, the authors investigate from an immunotherapy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.